Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Aug 2016
Randomized Controlled TrialOPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated with production of proinflammatory mediators. OPA-15406 is a phosphodiesterase-4 inhibitor with high selectivity for phosphodiesterase-4-B. ⋯ OPA-15406 ointment may provide an effective therapeutic modality for patients with mild to moderate AD.
-
J. Am. Acad. Dermatol. · Jan 2016
Randomized Controlled TrialApremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis. ⋯ Apremilast reduces the severity of nail/scalp psoriasis.
-
J. Am. Acad. Dermatol. · Sep 2015
Randomized Controlled Trial Comparative StudySecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). ⋯ Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe psoriasis and improving health-related quality of life with a comparable safety profile over 16 weeks.
-
J. Am. Acad. Dermatol. · Jul 2015
Randomized Controlled Trial Multicenter StudyApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Apremilast works intracellularly to regulate inflammatory mediators. ⋯ Apremilast was effective in moderate to severe plaque psoriasis.
-
J. Am. Acad. Dermatol. · Mar 2015
Randomized Controlled TrialEfficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
Novel therapies are needed for difficult-to-treat populations of patients with psoriasis. ⋯ Brodalumab is efficacious in patients with psoriasis with or without a history of PsA or biologic use.